These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 1332440)

  • 1. Pharmacokinetics of heparin and of dermatan sulfate: clinical implications.
    Boneu B; Caranobe C; Salvin S; Dol F; Sié P
    Adv Exp Med Biol; 1992; 313():237-47. PubMed ID: 1332440
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics of heparin and related polysaccharides.
    Boneu B; Dol F; Caranobe C; Sie P; Houin G
    Ann N Y Acad Sci; 1989; 556():282-91. PubMed ID: 2544127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-molecular-weight heparin and dermatan sulfate end group-labeled with tyramine and fluorescein. Biochemical and biological characterization of the fluorescent-labeled heparin derivative.
    Harenberg J; Casu B; Guerrini M; Malsch R; Naggi A; Piazolo L; Torri G
    Semin Thromb Hemost; 2002 Aug; 28(4):343-54. PubMed ID: 12244481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A chronopharmacodynamic study on standard heparin, a low molecular weight heparin (nadroparin) and danaproid: establishing and comparing the daily variations of these drugs in rats.
    Abrial D; Blanc A; Réhailia M; Mismetti P; Bouchut C; Laporte-Simitsidis S; Decousus H; Buisson B
    Haemostasis; 2000; 30(5):233-42. PubMed ID: 11251330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological actions of sulodexide.
    Ofosu FA
    Semin Thromb Hemost; 1998; 24(2):127-38. PubMed ID: 9579633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma anticoagulant mechanisms of heparin, heparan sulfate, and dermatan sulfate.
    Ofosu FA; Buchanan MR; Anvari N; Smith LM; Blajchman MA
    Ann N Y Acad Sci; 1989; 556():123-31. PubMed ID: 2525356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits.
    Blajchman MA; Young E; Ofosu FA
    Ann N Y Acad Sci; 1989; 556():245-54. PubMed ID: 2544126
    [No Abstract]   [Full Text] [Related]  

  • 8. Mechanisms for the anticoagulant effect of heparin and related polysaccharides.
    Ofosu FA
    Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma.
    Okwusidi JI; Anvari N; Kulczycky M; Blajchman MA; Buchanan MR; Ofosu FA
    J Lab Clin Med; 1991 May; 117(5):359-64. PubMed ID: 2019790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of factor X and factor V activation by dermatan sulfate and a pentasaccharide with high affinity for antithrombin III in human plasma.
    Ofosu FA; Choay J; Anvari N; Smith LM; Blajchman MA
    Eur J Biochem; 1990 Oct; 193(2):485-93. PubMed ID: 2226466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulant mechanisms of Orgaran (Org 10172) and its fraction with high affinity to antithrombin III (Org 10849).
    Ofosu FA
    Haemostasis; 1992; 22(2):66-72. PubMed ID: 1379966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dermatan sulfate and the prevention of experimental venous thrombosis].
    Desnoyers P; Bara L; Samama M
    Pathol Biol (Paris); 1989 Jun; 37(6):759-67. PubMed ID: 2674877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Covalent complexes between low molecular weight heparin fragments and antithrombin III - inhibition kinetics and turnover parameters.
    Hoylaerts M; Holmer E; de Mol M; Collen D
    Thromb Haemost; 1983 Apr; 49(2):109-15. PubMed ID: 6868006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of new synthetic heparin mimetics.
    Hérault JP; Bernat A; Roye F; Michaux C; Schaeffer P; Bono F; Petitou M; Herbert JM
    Thromb Haemost; 2002 Jun; 87(6):985-9. PubMed ID: 12083506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Hirsh J; Bauer KA; Donati MB; Gould M; Samama MM; Weitz JI
    Chest; 2008 Jun; 133(6 Suppl):141S-159S. PubMed ID: 18574264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale behind the development of low molecular weight heparin derivatives.
    Hirsh J; Ofosu F; Buchanan M
    Semin Thromb Hemost; 1985 Jan; 11(1):13-6. PubMed ID: 2579436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of oversulphated chondroitin and dermatan sulphate upon thrombin and factor Xa inactivation by antithrombin III or heparin cofactor II.
    Scully MF; Ellis V; Seno N; Kakkar VV
    Biochem J; 1988 Sep; 254(2):547-51. PubMed ID: 2902851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New antithrombotic agents for the prevention and treatment of deep vein thrombosis.
    Boneu B
    Haemostasis; 1996 Oct; 26 Suppl 4():368-78. PubMed ID: 8979141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The anticoagulant activity of dermatan sulphates: evidence against the involvement of antithrombin III.
    Kindness G; Long WF; Williamson FB
    Br J Pharmacol; 1981 Jan; 72(1):81-8. PubMed ID: 7225714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dermatan sulfate and heparin can be fractionated by affinity for heparin cofactor II.
    Griffith MJ; Marbet GA
    Biochem Biophys Res Commun; 1983 Apr; 112(2):663-70. PubMed ID: 6687802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.